Treatment of Cancer
Since the first edition was published in 1982, Treatment of Cancer has become a standard text for postgraduate physicians in the UK and beyond, providing all information necessary for modern cancer management in one comprehensive but accessible volume. By inviting experts from a number of disciplines to share their knowledge, the editors have succeeded in delivering a truly integrated approach to the care of the patient with cancer.
This fifth edition adopts the successful structure of previous editions, whilst being thoroughly revised and updated, and with several completely new chapters, covering important topics such as drug development, cancer prevention, and economics of cancer care, as well as treatments such as radioimmunotherapy, biological therapies and antibody therapy.
Part One considers the scientific basis and fundamental principles underlying cancer treatment and examines the likely developments that will occur over the next decade at the leading edge of oncology. Part Two is divided into two sections; the first covering general issues of cancer management, including planning techniques, concomitent chemoradiotherapy, surgical oncology and palliative care; and the second using a system-based approach to cover the clinical aspects and management plans for the whole spectrum of malignant disease.
Treatment of Cancer surpasses other oncology texts in condensing the essential information for exemplary cancer care into one readable and accessible guide, and will be an invaluable addition to the bookshelves of the busy oncologist in training or in practice.
What people are saying - Write a review
Other editions - View all
activity adjuvant agents angiogenesis antigen apoptosis assessment bevacizumab biopsy bone brain breast cancer Cancer Res carboplatin carcinoma cell lung cancer cent of patients cetuximab chemotherapy cisplatin Clin Endocrinol Clin Oncol clinical trials colorectal combination cytokines cytotoxic detection diagnosis disease dose drug effects EGFR etoposide fractions gene therapy genetic glioma growth factor head and neck human imaging immune increased inhibition inhibitors IntJ invasion involved irinotecan irradiation lesions lung cancer lymphoma malignant median melanoma metastatic molecular monoclonal antibody mutations neck cancer non-small cell lung normal tissues Oncol Biol Phys Oncology paclitaxel phase pituitary primary tumour prognostic protein Radiat Oncol Biol radioimmunotherapy Radiother radiotherapy randomized trial receptor recurrence regimens relapse resection response rates risk rituximab role scan squamous stage surgery surgical syndrome tamoxifen target techniques therapeutic thyroid cancer tion tiuxetan toxicity trastuzumab treated treatment tumour cells vaccines vascular vectors versus